therapeutics

Pfizer To Buy Global Blood Therapeutics In $Five Four Billion Deal

The B.1.1.7 variant now dominates in the UK and these benefits will largely reflect vaccine effectiveness against this variant. The investigators identified 94,354 vaccine recipients and matched them to 94,354 unvaccinated controls baseline demographic and clinical traits have been equivalent involving the two groups. In this evaluation, vaccine effectiveness against symptomatic COVID-19 was 57% (95% CI, 39-71) on days 14 to 20 soon after the 1st dose, 82% (95% CI, 73-91) on days 21 to 27 soon after the first dose and 93% (95% CI, 88-97) on days 7 to 21 right after the second dose. Couple of or no...